Eli Eyal - Concepedia

Concepedia

Author

Eli Eyal

Teva Pharmaceuticals (Israel)

Also Known As

E Eyal, E. Eyal, Eli Eyal, Eli Eyal, MSc, Eyal E

29

Publications

1.2K

Citations

16

H-Index

29

Concepts

All Affiliations

Teva Pharmaceuticals (Israel)Teva Pharmaceuticals (United States)Toronto Western Hospital Innsbruck Medical University Inserm

EE

About

Eli Eyal is an author at Teva Pharmaceuticals (Israel) specializing in neurology, medicine, and parkinson disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	521
2	Neurology	6	6	521
3	Pharmacology	3	3	175
4	Neuroscience	2	2	272
5	Health Sciences	1	1	10

Eli Eyal

×

17

Publications

1.2K

Citations

15

H-Index

	Year	Citations
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes Olivier Rascol, Cheryl Fitzer‐Attas, Robert A. Hauser, The Lancet Neurology Additional TherapiesParkinson DiseaseClinical NeurologyAdagio StudyClinical Neuroscience	2011	211
A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics C. Warren Olanow, Robert A. Hauser, Joseph Jankovic, Movement Disorders	2008	166
Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study Kara M. Smith, Eli Eyal, Daniel Weintraub JAMA Neurology	2014	104
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study Ralf Reilmann, Andrew McGarry, Igor D. Grachev, The Lancet Neurology Neurodegenerative DiseasesMedicinePsychotropic MedicationPsychopharmacologyPharmacotherapy	2018	104
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial Werner Poewe, Klaus Seppi, Cheryl Fitzer‐Attas, The Lancet Neurology Parkinsonian VariantParkinson DiseaseMultiple System AtrophyClinical NeurologyPlacebo-controlled Trial	2014	95
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers Iris Grossman, Nili Avidan, Clara Singer, Pharmacogenetics and Genomics	2007	72
Immunomodulatory placental‐expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty Tobias Winkler, Carsten Perka, Philipp von Roth, Journal of Cachexia Sarcopenia and Muscle	2018	62
Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study Mario Masellis, S.Karen Collinson, Natalie Freeman, Brain Molecular PharmacologyNeurodegenerative DiseasesSingle Nucleotide PolymorphismsMedicineGenetics	2016	61
Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's disease Robert A. Hauser, Dee E. Silver, Azhar Choudhry, Movement Disorders	2014	55
Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users Megan J. Shram, Orit Cohen‐Barak, Bijan Chakraborty, Journal of Clinical Psychopharmacology	2015	50

Page 1